Outcome of Patients With Differentiated Thyroid Cancer Treated With 131-Iodine on the Basis of a Detectable Serum Thyroglobulin Level After Initial Treatment

Michele Klain 1, Leonardo Pace 2*, Emilia Zampella 1, Teresa Mannarino 1, Simona Limone 1, Emanuela Mazziotti 1, Giovanni De Simini 1 and Alberto Cuocolo 1

1 Dipartimento di Scienze Biomediche Avanzate, Università degli Studi di Napoli Federico II, Napoli, Italy; 2 Dipartimento di Medicina, Chirurgia ed Odontoiatria Scuola Medica Salentiana, Università Degli Studi di Salerno, Salerno, Italy

Background: In patients with differentiated thyroid cancer (DTC) and raising serum thyroglobulin (Tg) after total or near-total thyroidectomy and 131I remnant ablation an empiric 131I therapy may be considered. However, outcome data after empiric therapy did not show a clear evidence of improved survival. We assessed the efficacy of such empiric 131I therapy in patients with DTC and evaluated the long-term outcome.

Methods: A total of 100 patients with DTC showing raised Tg level during follow-up after thyroidectomy and 131I ablation were treated with a further 131I therapy (6.1 ± 1.7 GBq). Whole-body scan (WBS) was performed 5–7 days after therapy. Tg value at 12 months after 131I therapy was considered as an indicator of treatment response: ≤1.5 ng/ml complete remission (CR), >50% decrease partial remission (PR), higher than pre-therapy progression disease (PD), all other cases stable disease (SD). Patients were followed-up for 96 ± 75 months.

Results: After 12 months, 62% of patients were in CR, 16% in PR, 8% in SD, and 14% in PD. WBS was positive in 41% of patients and negative in 59% (P = NS). Among patients with local recurrences at WBS 89% showed either CR or PR, while 71% of patients with distant metastases were in SD or PD (P < 0.001). Distant metastases at WBS (P < 0.05), CR (P < 0.0001), and CR + PR (P < 0.0001) were predictors of both progression free survival and overall survival.

Conclusion: There is a beneficial effect of 131I therapy on outcome of patients with DTC treated on the basis of elevated Tg value. In these patients, survival is affected by achievement of CR or PR at 12 months evaluation after 131I therapy and by the presence of distant metastases at WBS.

Keywords: differentiated thyroid carcinoma, 131I empiric therapy, prognosis, thyroglobulin, whole body scan
INTRODUCTION

Follow-up of patients with differentiated thyroid cancer (DTC) after total or near-total thyroidectomy and 131I remnant ablation is performed by assessment of thyroglobulin (Tg) levels, ultrasonography, and 131I diagnostic whole-body scan (d-WBS). The most reliable parameter for the detection of tumor recurrence is a raised Tg level, which suggests persistence or recurrence of viable tumor tissue (1–5). In these patients an empiric 131I therapy may be considered (6), although there is still no agreement on the cutoff value of serum Tg above which a patient should be treated with an empiric 131I dose. It has been reported that patients with stimulated serum Tg ≥ 5 ng/ml are unlikely to have a decline without therapy, while a high rate of subsequent structural recurrence has been reported (7, 8). In these patients, administration of high activity of 131I would have both a diagnostic and therapeutic intent. Actually, a decrease in Tg levels after empiric 131I therapy has been demonstrated in 56–63% of such patients and in 61% of them post-therapy. 131I whole-body scan (t-WBS) was positive (9, 10). Yet, data on outcome after empiric therapy in this setting did not show a clear evidence of improved survival (11–13).

Therefore, the aims of this study were to assess the efficacy of a high-dose 131I therapy administered only on the basis of a raised serum Tg level in patients with DTC after initial treatment and to evaluate the long-term outcome.

MATERIALS AND METHODS

Study Population and Design

Among 1,115 patients with DTC treated with total or near-total thyroidectomy followed by 131I ablation between 1998 and 2006, those (n = 100) showing raised (i.e., >5 ng/ml) serum Tg level during follow-up were included in this retrospective study. The study protocol is outlined in Figure 1. After 131I ablation, L-thyroxine therapy for TSH suppression was performed in all patients according to the American Thyroid Association (ATA) guidelines (6). Results of 131I ablation were evaluated after 12 months by Tg assessment off L-thyroxine therapy, d-WBS and neck ultrasound. All patients underwent d-WBS while off L-thyroxine therapy for 3 weeks. Imaging was performed 48 h after administration of 250 MBq of 131I using a dual-head gamma camera (E.CAM, Siemens Medical Systems, Hoffman Estates, IL, USA) equipped with a high-energy, general purpose collimator and connected with a dedicated computer system. Exclusion criteria were: positive serum anti-Tg antibody and a d-WBS scan 12 months after 131I ablation demonstrating thyroid remnant or secondary lesions. Hence, all patients showed an excellent response after ablation (6). For empiric 131I therapy, L-thyroxine was discontinued for 20–30 days until the TSH augmented (≥25–30 mIU/l). At that time, Tg concentration was measured and 131I was administered (6.1 ± 1.7 GBq). Five to seven days later, t-WBS was performed.

Since all patients had a negative d-WBS 12 months after 131I ablation, the presence of tracer uptake in the cervical region at t-WBS performed after empiric 131I therapy was considered as local recurrence, while uptake in other regions was considered as distant metastases. The presence of local recurrence and distant metastases was confirmed by additional imaging procedures such as ultrasound, computed tomography, and/or bone scintigraphy, as appropriate.

Response to 131I empiric therapy was evaluated by assessing the serum Tg level 12 months after empiric therapy. In particular, a Tg value ≤1.5 ng/ml was considered as complete remission (CR), a decrease >50% as partial remission (PR), a level higher than the pre-therapy value as progression disease (PD), while all other cases were considered to be in stable disease (SD) (14). Thereafter, patients were followed by Tg level determinations (on L-thyroxine and off L-thyroxine therapy, as requested) every 6–12 months and imaging procedures as appropriate, with a mean follow-up of 96 ± 75 months (range 12–276 months). Disease status was recorded at each evaluation time point. Progression free survival (PFS) was measured from the date of empiric 131I therapy to the first observation of progressive disease (PD), relapse, need for additional therapy (i.e., 131I therapy or surgery), or death. Relapse of disease was defined as evidence of disease during follow-up after empiric 131I therapy by histological or imaging procedures, as appropriate, in patients with proven DTC and stimulated Tg levels > 2 ng/ml (15). Patients last known to be alive and progression free were censored at date of last contact. Overall survival (OS) was measured from the date of registration to the date of death.

Figure 1 | Outline of the study protocol.
**Statistical Analysis**

MedCalc Statistical Software version 13.1.2 was used for statistical analysis (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2014). Continuous data were tested for normal distribution by the D’Agostino-Pearson test. Data were expressed as mean ± standard deviation, median and range or as proportions, as appropriate. Differences among groups were analyzed by analysis of variance, Kruskal-Wallis test, or by chi square analysis, as appropriated. Univariate and multivariate logistic analyses of clinical and imaging variables were performed using using Cox proportional hazards regression. Only significant variables at univariate analysis were included in the multivariate model. Survival analysis was performed using Kaplan-Meier method and log-rank test. Survivors were censored at the time of last clinical control. A P < 0.05 was considered statistically significant.

**RESULTS**

Among 100 patients (68 women and 32 men; mean age 46 ± 16 years, range 20–82 years) enrolled, 16 had follicular cancer, and 84 papillary cancer. At initial staging, after surgery and $^{131}$I ablation, 60 patients were in stage I, 10 in stage II, 23 in stage III, and 7 in stage IVa. According to the ATA risk stratification system, 43 patients were in low, 41 in intermediate, and 16 in high-risk group. t-WBS performed at $^{131}$I ablation was negative in 5 patients and showed tracer uptake in the cervical region (i.e., thyroid remnant) in 95 patients. Differently, d-WBS performed 12 months after $^{131}$I ablation was negative in all patients. t-WBS performed after empiric $^{131}$I therapy was negative in 59 patients and positive in 41. Among patients with positive scan, 27 presented local recurrence and 14 distant metastases (7 lung metastases, 4 bone metastases, and 3 both). **Table 1** shows the characteristics of patients according to response to empiric $^{131}$I therapy after 12 months of treatment. Of all patients, 62 were in CR, 16 in PR, 8 in SD, and 14 showed PD. CR was evident in 67% of papillary DTC and in 37% of follicular DTC, PR in 17% of papillary DTC and in 13% of follicular DTC, SD in 7% of papillary DTC and in 13% of follicular DTC, PD in 10% of papillary DTC, and in 37% of follicular DTC ($P < 0.01$). A significant association ($P < 0.001$) between initial staging and response to empiric therapy was found, with the majority (83%) of patients in earlier stage (i.e., I and II) showing either CR or PR. Similarly, the response to empiric therapy was significantly ($P < 0.01$) associated with the initial ATA patients risk classification: 81% (35/43) of patients in low risk class showed either CR or PR. Pre-therapy Tg was higher in PD than in CR patients (**Table 1**). There was no statistical difference in the percentage of patients showing CR, PR, SD, and PD between negative and positive t-WBS (69, 15, 15, and 12% vs. 51, 17, 15, and 17%, respectively). However, when positive t-WBS were subdivided according to site of uptake, 89% of those with local recurrences showed either CR or PR, while 71% of patients with distant metastases at t-WBS were in SD.

**Table 1** Characteristics of patients according to $^{131}$I therapy response.

| Age (years) | CR ($n = 62$) | PR ($n = 16$) | SD ($n = 8$) | PD ($n = 14$) | p-value |
|------------|---------------|---------------|--------------|--------------|---------|
| 42 ± 16    | 53 ± 16       | 46 ± 19       | 52 ± 15      |              | 0.06    |
| Female gender | 41            | 10            | 6            | 11           | 0.7     |
| Papillary ($n$) | 56            | 14            | 6            | 8            | <0.01   |
| Follicular ($n$) | 6             | 2             | 2            | 6            |         |
| STAGE      |               |               |              |              |         |
| I          | 45            | 6             | 3            | 6            | <0.001  |
| II         | 1             | 6             | 1            | 2            |         |
| III        | 12            | 3             | 2            | 6            |         |
| IV         | 4             | 1             | 2            | 0            |         |
| ATA RISK GROUP |              |               |              |              |         |
| Low        | 24            | 11            | 2            | 6            | <0.01   |
| Intermediate | 28            | 3             | 2            | 8            |         |
| High       | 10            | 2             | 4            | 0            |         |
| Time interval between therapy (months) | 24 (12–240) | 24 (12–96) | 27 (12–96) | 25 (12–96) | 0.5     |
| Pre-therapy Tg level (ng/ml) off<sup>a</sup> | 13.5 (5–6,000) | 56.8 (8–2,107) | 60.5 (12–1,000) | 62.2 (5–500) | <0.001 |
| Administered 131-I activity (GBq) | 3.7 (3.7–7.4) | 5.2 (3.7–7.4) | 5.5 (3.7–7.4) | 5.2 (3.7–7.4) | 0.09    |
| POST-THERAPY WBS |              |               |              |              |         |
| Negative   | 41            | 9             | 2            | 7            | <0.001  |
| Local disease | 18            | 6             | 2            | 1            |         |
| Distant metastases | 3             | 1             | 4            | 6            |         |

*Data are presented as mean ± SD or median (range). |
*off L-thyroxine therapy.
or PD (Table 1), and this difference was statistically significant \((P < 0.001)\). At multivariate logistic analysis, only these results of t-WBS were significant determinants of \(^{131}\)I therapy response, either CR or PR (odds ratio 0.32, 95% confidence interval 0.17–0.62, \(P < 0.001\)) (Table 2).

During subsequent follow-up (mean 96 ± 75 months, range 12–276) 38 patients showed progressive disease or relapse and 6 died of thyroid cancer (Figure 2). Of the 38 patients with progressive disease or relapse, 13 (34%) were in CR, 10 (26%) in PR, 4 (11%) in SD, and 11 (29%) had PD at 12 months evaluation after empiric \(^{131}\)I therapy (\(P < 0.0001\)). Four of these 38 patients underwent surgery for lymph node recurrence and 34 further therapies with \(^{131}\)I (one additional therapy in 18 patients, two additional therapies in 11 patients, and three or more therapies in 9 patients). Of these latter 34 patients, 18 were retreated for PD (positive t-WBS after empiric \(^{131}\)I therapy) and 16 for persistent high Tg levels. Of the 38 patients with progressive disease or relapse, 13 (34%) were in CR, 10 (26%) in PR, 4 (11%) in SD, and 11 (29%) had PD at 12 months evaluation after empiric therapy (\(P = 0.6\)). Of the same 6 patients, 2 (33%) were in stage I, 3 (50%) in stage III, and 1 (17%) in stage IV (\(P = 0.6\)). Also, 5 (83%) patients were in the ATA intermediate risk group and 1 (17%) in the high-risk group (\(P = 0.2\)).

Fifty percent of patients with a positive t-WBS and 32% of those with a negative t-WBS showed progressive disease or relapse (\(P < 0.05\)). In particular, 46% of patients with regional uptake at t-WBS and 73% of those showing distant metastases had progressive disease or relapse. Of the 6 patients who died during follow-up, none was in CR at 12 months evaluation after empiric therapy and 4 had a positive t-WBS (3 with distant metastases). At univariate analysis, distant metastases (\(P < 0.05\)), CR (\(P < 0.0001\)) and CR + PR (\(P < 0.0001\)) were predictors of PFS (Table 3). Figure 3 shows the PFS at Kaplan-Meier analysis according to presence of distant metastases, CR and CR + PR. At multivariate analysis, only CR was retained in the model (\(P < 0.0001\)). At univariate analysis, distant metastases (\(P < 0.05\)), CR (\(P < 0.0001\)), and CR + PR (\(P < 0.0001\)) were significant predictors of OS (Table 3). Figure 4 shows the OS at Kaplan-Meier analysis according to presence of distant metastases, CR and CR + PR. At multivariate analysis, only CR or PR was retained in the model (\(P < 0.0001\)).

**DISCUSSION**

In this retrospective follow-up study of patients treated with \(^{131}\)I empiric therapy on the basis of elevated Tg, post-therapy WBS was positive in 41% of the patients and complete biochemical remission 12 month after \(^{131}\)I empiric therapy was observed in 62% of the entire population. Results of therapy were not

### TABLE 2

| Univariate | Multivariate |
|------------|--------------|
| Odds ratio (95% CI) | p-value | Odds ratio (95% CI) | p-value |
| Age | 0.39 (0.14 – 1.06) | 0.06 | 0.32 (0.17 – 0.62) | <0.001 |
| Female gender | 0.56 (0.18 – 1.87) | 0.06 | 0.41 (0.16 – 1.10) | 0.08 |
| Histology (papillary) | 0.18 (0.06 – 0.58) | 0.005 | 0.70 (0.26 – 1.18) | 0.5 |
| Tg pre-therapy off L-thyroxine therapy | 1.0 (0.99 – 1.01) | 0.8 | 1.0 (0.99 – 1.01) | 0.7 |
| Stage (I and II vs. III and IV) | 0.41 (0.16 – 1.10) | 0.08 | 0.39 (0.15 – 1.02) | 0.06 |
| ATA risk class (low vs. intermediate and high) | 1.0 (0.99 – 1.01) | 0.8 | 1.0 (0.99 – 1.01) | 0.8 |

CI, confidence interval.

**FIGURE 2** | Response to empiric \(^{131}\)I therapy: assessment at 12 months and subsequent follow-up. CR, complete remission; PR, partial remission; SD, stable disease; PD, progression disease.
related to age and gender, while patients with lower values of pretherapy Tg achieved more frequently CR. Moreover, remission was more probable in patients in earlier stage of disease at presentation and in those in low-risk class as well as in patients not showing distant metastases at t-WBS performed after empiric 
$^{131}$I therapy. Both PFS and OS were better in patients showing remission at 12 months evaluation after empiric therapy as in those not showing distant metastases at t-WBS performed after empiric therapy.

According to ATA guidelines, 
$^{131}$I therapy is suggested in patients with elevated serum Tg levels when imaging did not show a tumor source amenable to directed therapy (6). While more than 50% of patients treated do have a reduction in Tg values (10, 16–18), improved survival has not been demonstrated (11–13). A large variability in percentage of patients showing positive t-WBS (ranging from 43 to 94%) has been reported, with a mean value of 61% (10, 19). On the other hand, the percentage of patients treated with 
$^{131}$I showing Tg values significantly decreased or undetectable Tg ranges from 20 to 72%, with a mean of 56% (10). No statistically significant difference in CR between patients with positive and negative t-WBS has been previously reported (11, 13, 16).

The results of our study confirm that 
$^{131}$I therapy administered on the basis of elevated Tg is effective independently from the results of t-WBS. However, it should be noted that while 67% of patients with loco-regional uptake had CR, only 21% of those showing distant metastases achieved CR. It has been reported that in patients with structurally identifiable metastatic DTC 
$^{131}$I therapy failed to cause disease regression or conversion from progressive to SD in any patient (20). Moreover, serum Tg levels after 
$^{131}$I therapy decreased more frequently in patients with micro-metastases than in those with macro-metastases (12, 17), and CR has been observed only in 24.2% of patients with lung metastases (21).

The rationale of empiric 
$^{131}$I therapy is both diagnostic and therapeutic. However, it has been reported a relatively low rate of detection of pathological uptake mainly in patients with negative WBS at ablation (22, 23). The percentage of patients with positive t-WBS in our study is 41%, in the range reported in the literature (9, 10), and it should be noted that in our study the results of t-WBS at ablation have not been considered among the inclusion criteria, while a negative d-WBS after 
$^{131}$I ablation was one of the inclusion criteria.

No definite data on outcome of patients treated with 
$^{131}$I therapy on the basis of elevated Tg are present in the literature (11–13). In 42 patients with negative WBS and elevated Tg treated with a therapeutic dose of 
$^{131}$I and followed-up for 6.7 ± 3.8 years, Pacini et al. (11) found resolution of 
$^{131}$I uptake in 88.8% of lung metastases and in 61.1% of cervical node metastases. In the subgroup of patients with negative t-WBS (n = 12) one patient died (11). Fatourechi et al. (12) showed in 24 consecutive patients treated with 
$^{131}$I therapy (follow-up 6–33 months) that progression was evident in 13 patients with macro-metastases and 5 died of thyroid cancer, while the disease remained stable in 7 patients with micro-metastases. However, no statistical survival analysis was performed in these studies (11, 12). In 56 patients with DTC with negative WBS and increased serum Tg, van Tol et al. (13) found a 5-year survival of 100% in the group with positive t-WBS and of 76% in the group with negative t-WBS (P < 0.001). It should be noted that in that study a higher percentage of patients with positive t-WBS reached

| TABLE 3 | Univariate predictors of progression free survival and overall survival based on clinical and imaging data. |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                | Progression free survival | Overall survival |                |                |                |
|                | $\chi^2$ | p-value | $\chi^2$ | p-value |
| Age            | 1.0     | 0.3     | 0.1     | 0.9     |
| Female gender  | 0.9     | 0.3     | 0.2     | 0.7     |
| Histology (papillary) | 1.5     | 0.2     | 0.7     | 0.5     |
| Tg pre-therapy off | 0.1     | 0.9     | 0.1     | 0.8     |
| L-thyroxine therapy |                |                |                |                |
| Stage (I and II vs. III and IV) | 1.9     | 0.2     | 3.8     | 0.5     |
| ATA risk class (low vs. intermediate and high) | 0.2     | 0.6     | 8.1     | <0.01   |
| Time interval between therapy | 0.9     | 0.7     | 0.4     | 0.5     |
| Administered activity | 1.9     | 0.2     | 0.4     | 0.5     |
| t-WBS (positive) | 3.3     | 0.06    | 2.3     | 0.1     |
| t-WBS (distant metastases) | 4.9     | <0.05   | 5.1     | <0.05   |
| Complete remission | 48.9    | <0.0001 | 15.8    | <0.0001 |
| Complete remission + partial remission | 32.0    | <0.0001 | 15.5    | <0.0001 |

FIGURE 3 | Progression-free survival (PFS) by Kaplan-Meier analysis and log-rank test based on the presence of distant metastases at therapeutic 
$^{131}$I whole body scan (WBS) (A) complete response at 12 months evaluation after 
$^{131}$I therapy (B) complete response + partial response at 12 months evaluation after 
$^{131}$I therapy (C). t-WBS, therapeutic 
$^{131}$I WBS; DM, distant metastases; CR, complete remission; PR, partial remission.
remission as compared to those with negative t-WBS (64 vs. 36%, \( P = 0.06 \)) (13).

In our study we evaluated long-term follow-up in a group of 100 patients. Our results show a better PFS in patients without distant metastases at t-WBS and in patients showing CR or PR at 12 months evaluations after \(^{131}\text{I}\) therapy; moreover, OS was better in patients without distant metastases at t-WBS and in patients showing CR or PR at 12 months evaluations after \(^{131}\text{I}\) empiric therapy. Since the need for additional therapy was one of the end points for PFS, it is not surprising to find the presence of distant metastases at t-WBS to be a significant predictor. On the other hand, also OS is predicted by the presence of distant metastases at t-WBS.

Besides its retrospective observational nature, our study had other limitations. A similar control cohort in which \(^{131}\text{I}\) therapy was not performed is not available. Moreover, in a retrospective analysis the ability to discern certain treatment effects is limited by small sample size and limited number of events. Therefore, a randomized controlled study, with a larger cohort of patients, is needed to assess the prognostic impact of the empiric \(^{131}\text{I}\) therapy in patients with raised Tg values.

**CONCLUSIONS**

The findings of this study suggest a beneficial effect of \(^{131}\text{I}\) therapy on the outcome of patients treated on the basis of elevated Tg value. However, survival is strongly affected by the achievement of remission, either complete or partial, at 12 months evaluation after \(^{131}\text{I}\) therapy and by the presence of distant metastases at t-WBS.

**DATA AVAILABILITY**

The datasets generated for this study are available on request to the corresponding author.

**ETHICS STATEMENT**

This study follows the principles expressed in the Declaration of Helsinki. All study participants waived informed consents owing to the retrospective analysis, and the study design was approved by the appropriate ethics review boards.

**AUTHOR CONTRIBUTIONS**

MK, LP, and AC contributed conception and design of the study. EM, GD, and TM collected the data and organized the database. LP and SL analyzed the data. MK and EZ wrote the first draft of the manuscript. All authors contributed to the final version of the manuscript.

**REFERENCES**

1. Ozata M, Suzuki S, Myamoto T, Liu RT, Fierro-Renoy F, Degrot LJ. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. *J Clin Endocrinol Metab.* (1994) 79:98–105.

2. Duren M, Siperstein AE, Sheen W, Duh QY, Morita E, Clark OH. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high and low-risk patients. *Surgery.* (1999) 126:13–9. doi: 10.1067/msy.1999.98849

3. Pacini F, Pinchera A. Serum and tissue thyroglobulin measurements: clinical applications in thyroid disease. *Biochimie.* (1999) 81:463–7. doi: 10.1016/S0300-9084(99)80096-0

4. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low risk patients with papillary thyroid carcinoma. *J Clin Endocrinol Metab.* (2003) 88:1433–41. doi: 10.1210/jc.2002-021702

5. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Tadei D, Pinchera A. Diagnostic \(^{131}\text{I}\) whole body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. *J Clin Endocrinol Metab.* (2002) 87:1499–501. doi: 10.1210/jcem.87.4.8274

6. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. *Thyroid.* (2016) 26:1–133. doi: 10.1089/thy.2015.0020

7. Padovani RP, Robenshtok E, Brokhin M, Tuttle RM. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in...
patients with differentiated thyroid cancer. *Thyroid*. (2012) 22:778–83. doi: 10.1089/thy.2011.0522

8. Yim JH, Kim EY, Bae KW, Kim WG, Kim TY, Ryu JS, et al. Long-term consequence of elevated thyroglobulin in differentiated thyroid cancer. *Thyroid*. (2013) 23:58–63. doi: 10.1089/thy.2011.0487

9. Ma C, Xie J, Kuang A. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results? *J Nucl Med*. (2005) 46:1164–70. Available online at: http://jnm.snmjournals.org/content/46/7/1164.long

10. Chao M. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan. *Clin Oncol*. (2010) 22:438–47. doi: 10.1016/j.clon.2010.05.005

11. Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. *J Clin Endocrinol Metab*. (2001) 86:4092–7. doi: 10.1210/jcem.86.9.7831

12. Fatourechi V, Hay ID, Javedan H, Wiseman GA, Mullan BP, Gorman CA. Lack of impact of radioiodine therapy in Tg-positive, diagnostic whole-body scan negative patients with follicular cell-derived thyroid cancer. *J Clin Endocrinol Metab*. (2002) 87:1521–6. doi: 10.1210/jcem.87.4.8373

13. van Tol KM, Jager PL, de Vries EG, Piers DA, Boezen HM, Sluiter WJ, et al. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. *Eur J Endocrinol*. (2003) 148:589–96. doi: 10.1530/ej.0.1480589

14. Pace L, Klain M, Albanese C, Salvatore B, Storto G, Sorcelli A, et al. Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment. *Eur J Nucl Med Mol Imaging*. (2006) 33:179–83. doi: 10.1007/s00259-005-1929-2

15. Hovens GC, Stokkel MP, Kievit J, Corssmit EP, Pereira AM, Romijn JA, et al. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. *J Clin Endocrinol Metab*. (2007) 92:2610–5. doi: 10.1210/jc.2006-2566

16. Koh JM, Kim ES, Ryu JS, Hong SJ, Kim WB, Shong YK. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study. *Clin Endocrinol*. (2003) 58:421–7. doi: 10.1046/j.1365-2265.2003.01733.x

17. Kabasakal L, Selcuk NA, Shafipour H, Ozmen O, Onsel C, Uslu I. Treatment of iodine-negative thyroglobulin positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases. *Eur J Nucl Med Mol Imaging*. (2004) 31:1500–4. doi: 10.1007/s00259-004-1516-y

18. Sinha P, Conrad GR, West HC. Response of thyroglobulin to radioiodine therapy in thyroglobulin-elevated negative iodine scintigraphy (TENIS) syndrome. *Anticancer Res*. (2011) 31:2109–12. Available online at: http://ar. iiarjournals.org/content/31/6/2109.long

19. Kalender E, Umu Elboga U, Çelen Y, Demir H, Sahin E, Seyhan Karacavus S. Empiric 131I treatment of high thyroglobulin levels in differentiated thyroid carcinoma after remnant ablation. *Acta Med Mediterranea*. (2014) 30:503–7. Available online at: http://www.actamedicamediterranea.com/archive/2014/medica-2/empiric-sup131supi-treatment-of-high-thyroglobulin-levels-in-differentiated-thyroid-carcinoma-after-remnant-ablation

20. Sabra MM, Grewal RK, Tala H, Larson SM, Tuttle RM. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans. *Thyroid*. (2012) 22:877–83. doi: 10.1089/thy.2011.0429

21. Song HJ, Qiu ZL, Shen CT, Wei WJ, Luo QY. Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. *Eur J Endocrinol*. (2015) 173:399–408. doi: 10.1530/EJE-15-0296

22. Kim WG, Ryu JS, Kim EY, Lee JH, Baek JH, Yoon JH, et al. Empiric high dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan. *Eur J Endocrinol Metab*. (2010) 95:1169–73. doi: 10.1530/ej.2009-1567

23. Rosario PW, Mourao GE, dos Santos JR, Caloslar MB. Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin? *Thyroid*. (2014) 24:533–6. doi: 10.1089/thy.2013.0427

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Klain, Pace, Zampella, Mammarino, Limone, Mazzotti, De Simini and Cuocolo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.